Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(3.04) per share which missed the analyst consensus estimate of $(2.27) by 34.22 percent. This is a 0.98 percent increase over losses of $(3.07) per share from the same period last year. The company reported quarterly sales of $741.000 thousand which beat the analyst consensus estimate of $500.000 thousand by 48.20 percent. This is a 40.72 percent decrease over sales of $1.250 million the same period last year.